Episode 38:  Q3 earnings are relatively weak but the revised estimates have been dumbed down to only around 4.5%…so a “surprise” beat expectations is probably cooked into the books.  Expect earnings growth to exceed 6%…which would be down from last quarter’s growth of 7.5% and way down from early estimates of double digit growth. In Part I we discuss Pharma... Read more →